Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 2:17 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 3097–3120 of 3,928 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HTN Clear all

Conditions: Pulmonary Hypertension
Interventions: Pulmonary Index of Microcirculatory Resistance, Right Ventricle Index of Microcirculatory Resistance; Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hypertension
Interventions: Amlodipine, Olmesartan medoxomil plus amlodipine; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 18
States / cities: Buena Park, California • Long Beach, California • Los Angeles, California + 15 more

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: PF-04217329, latanoprost vehicle, latanoprost; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 8
States / cities: Cypress, California • Garden Grove, California • Gardena, California + 4 more

Conditions: Traumatic Brain Injury, Acute Brain Injuries, Intracranial Hypertension
Interventions: Optic nerve ultrasound; Device
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Obesity, Hypertension
Interventions: Lifestyle Modification Program, Usual Care and Reading Materials; Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 21 Years and older
Enrollment: 365 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypertensive Disorders of Pregnancy (HDP)
Interventions: HEART at Home; Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Respiratory Impairment, Elevated Blood Pressure, Physical Inactivity
Interventions: Increased lifestyle walking (intervention), Health education only (control); Other
Lead sponsor: Iowa State University; Other
Eligibility: 65 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Ames, Iowa

Conditions: Open-angle Glaucoma
Interventions: Anecortave Acetate Sterile Suspension, 30 mg/mL, Anecortave Acetate Vehicle; Drug · Other
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Alzheimer's Disease, Hypertension
Interventions: Ramipril, Placebo; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 40 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: Alcon Investigational Agent; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Multiple Locations Throughout the United States, Texas

Conditions: Idiopathic Pulmonary Arterial Hypertension.
Interventions: Albuterol., Normal saline placebo; Drug
Lead sponsor: American Medical Association Foundation; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Normal Tension Glaucoma
Interventions: Not listed
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Obesity, Hypertension, Hyperglycemia
Interventions: losartan, Placebo control; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 9
States / cities: Little Rock, Arkansas • San Diego, California • Miami, Florida + 6 more

Conditions: Infection, Heart Failure, Chronic Obstructive Pulmonary Disease, Asthma, Gout Flare, Chronic Kidney Diseases, Hypertensive Urgency, Atrial Fibrillation Rapid, Anticoagulants; Increased
Interventions: Potassium estimation algorithm; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Uncontrolled Hypertension
Interventions: Celcius Thermacool Catheter or Chilli II Cooled Ablation Catheter; Device
Lead sponsor: Vivek Reddy; Other
Eligibility: 18 Years to 85 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Glaucoma, Tumors, Age-Related Macular Degeneration
Interventions: high frequency ultrasound examination; Procedure
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1996 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Hypertension, Dyslipidemia
Interventions: Pumpkin seed oil, Pumpkin seeds; Dietary Supplement
Lead sponsor: Texas Woman's University; Other
Eligibility: Female only
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pulmonary Arterial Hypertension
Interventions: Seralutinib, Gereic Dry Powder Inhaler; Drug · Device
Lead sponsor: Gossamer Bio USA, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 33
States / cities: Fresno, California • Los Angeles, California • Sacramento, California + 26 more

Conditions: Chronic Venous Hypertension With Ulcer
Interventions: ActiVAC System, Compression therapy; Device · Other
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Preeclampsia, Obstetric Labor Complications, Hypertension in Pregnancy
Interventions: Pravastatin, Placebo; Drug · Other
Lead sponsor: The George Washington University Biostatistics Center; Other
Eligibility: 16 Years and older · Female only
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 12
States / cities: Birmingham, Alabama • Chicago, Illinois • New York, New York + 9 more

Conditions: Pulmonary Hypertension
Interventions: Nitric Oxide/INP Pulse Delivery, Nitric Oxide/INO Pulse Delivery; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hypertension
Interventions: Azilsartan Medoxomil Low-dose, Losartan, Placebo for Azilsartan Medoxomil, Placebo for Losartan, Azilsartan Medoxomil Medium-dose (20 mg), Azilsartan Medoxomil High-dose (40 mg); Drug
Lead sponsor: Arbor Pharmaceuticals, Inc.; Industry
Eligibility: 6 Years to 18 Years
Enrollment: 377 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 17
States / cities: Anaheim, California • Hialeah, Florida • Miami, Florida + 12 more

Conditions: Obesity, Childhood, Behavior, Eating
Interventions: Age-specific educational materials and monitoring; Behavioral
Lead sponsor: Corewell Health East; Other
Eligibility: 2 Years to 17 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Hypertension, Aortic Stenosis, Calcific, Quality of Life, Heart Failure With Preserved Ejection Fraction
Interventions: Eplerenone; Drug
Lead sponsor: North Florida Foundation for Research and Education; Other
Eligibility: 55 Years to 100 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Gainesville, Florida

Search by objective public record fields.

Novel Index (PIMR) in PAH

Blood Pressure Lowering Ability and Safety of an Olmesartan and Amlodipine Based Treatment Regimen in Patients With Stage I and Stage II Hypertension

A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329

Automated Measurement of Optic Nerve Sheath Diameter

Evaluating a Blood Pressure Reduction and Weight Loss Program in a Low Income, Ethnically Diverse Population (The Be Fit, Be Well [BFBW] Study)

Postpartum Home Visiting (HEART at Home)

Walking and Blood Pressure in Older Adults With Respiratory Impairment.

Safety and Efficacy of Anecortave Acetate in Patients With Open-Angle Glaucoma

Studying the Effects of Antihypertensives on Individuals at Risk for Alzheimer's

Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-01-69

Albuterol and Dynamic Hyperinflation in Idiopathic Pulmonary Arterial Hypertension

IOP Lowering Effects of Topical Anesthetics Used Frequently in the Ophthalmology Clinic

A Randomized Clinical Trial To Study Losartan On Endothelial Dysfunction and Insulin Resistance In Obese Patients

Serum Potassium Prediction Using Machine Learning and Single-lead ECG

Impact of Renal SympAthetic DenerVation on Chronic HypErtension

Ultrasonic Evaluation of Ocular Tissues

Effect of Pumpkin Seed Oil or Pumpkin Seeds on Blood Pressure and Menopausal Symptoms in Postmenopausal Women

Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)

ActiV.A.C.+ Compression Therapy Versus Compression Therapy Alone for the Treatment of Chronic Venous Ulcerations

Pravastatin to Prevent Preeclampsia

Cardiopulmonary Function Assessment and NO-Based Therapies for Patients With Hemolysis-Associated Pulmonary Hypertension

An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With Hypertension

Pediatric Obesity Management Study

Pressure Assessment to Improve Outcomes After TAVR: a Registry